Email this article 
Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia
- Authors: Lomaia E.G.1, Romanova E.G.1, Sbityakova E.I.2, Zaritskiy A.Y.2
-
Affiliations:
- Almazov Federal Heart, Blood and Endocrinology Center, Ministry of Health of Russia
- Almazov Federal Heart, Blood and Endocrinology Center, Ministry of Health of Russia Saint Petersburg Pavlov State Medical University, Ministry of Health of Russia
- Issue: Vol 8, No 2 (2013)
- Pages: 22-33
- Section: HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CARE
- Published: 22.05.2013
- URL: https://oncohematology.abvpress.ru/ongm/article/view/30
- DOI: https://doi.org/10.17650/1818-8346-2013-8-2-22-33
- ID: 30
Cite item
Full Text
Abstract
Current treatment options for chronic myeloid leukemia (CML) with imatinib allowed achieving long-term progression-free and overall survival and improved patient quality of life. In cases of imatinib resistance therapy with second-generation tyrosine kinases inhibitors – dasatinib and nilotinib – is also possible. The article represents a literature review evaluating efficacy and toxicity of both drugs and highlighting some of the practical issues of CML treatment after first-line therapy failure.
Keywords
About the authors
E. G. Lomaia
Almazov Federal Heart, Blood and Endocrinology Center, Ministry of Health of Russia
Author for correspondence.
Email: lomelza@gmail.com
Russian Federation
E. G. Romanova
Almazov Federal Heart, Blood and Endocrinology Center, Ministry of Health of RussiaRussian Federation
E. I. Sbityakova
Almazov Federal Heart, Blood and Endocrinology Center, Ministry of Health of RussiaSaint Petersburg Pavlov State Medical University, Ministry of Health of Russia
Russian Federation
A. Yu. Zaritskiy
Almazov Federal Heart, Blood and Endocrinology Center, Ministry of Health of RussiaSaint Petersburg Pavlov State Medical University, Ministry of Health of Russia
Russian Federation
References
Supplementary files
